Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Months
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals (NASDAQ: BDRX) announced positive Phase 2 clinical trial results for its newly-licensed eRapa in treating Familial Adenomatous Polyposis (FAP). The trial showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden. These results will be presented at the 2024 Digestive Disease Week annual meeting.
May 21, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals reported positive Phase 2 clinical trial results for eRapa in treating Familial Adenomatous Polyposis, showing an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden. These results will be presented at the 2024 Digestive Disease Week annual meeting.
The positive Phase 2 trial results and the upcoming presentation at a prestigious medical conference are likely to boost investor confidence and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100